These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2908595)

  • 1. Detection of residual disease in acute leukemia using immunological markers.
    Ryan DH; van Dongen JJ
    Cancer Treat Res; 1988; 38():173-207. PubMed ID: 2908595
    [No Abstract]   [Full Text] [Related]  

  • 2. CAMAL: a new prognostic marker for remission in acute nonlymphoblastic leukemia.
    Logan PM; Whitney S; Naiman S; Levy JG
    Leuk Res; 1988; 12(1):19-24. PubMed ID: 3282127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double marker analysis for terminal deoxynucleotidyl transferase and myeloid antigens in acute nonlymphocytic leukemia patients and healthy subjects.
    Adriaansen HJ; Hooijkaas H; Kappers-Klunne MC; Hählen K; van't Veer MB; van Dongen JJ
    Haematol Blood Transfus; 1990; 33():41-9. PubMed ID: 2323649
    [No Abstract]   [Full Text] [Related]  

  • 4. Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement.
    Freedman AS; Takvorian T; Nadler LM; Anderson KC; Sallan SE; Ritz J
    Cancer Treat Res; 1988; 38():265-83. PubMed ID: 2908599
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of monoclonal antibodies and immune markers in the diagnosis, prognosis, and therapy of acute leukemia.
    Neame PB; Soamboonsrup P; Quigley JG; Pewarchuck W
    Transfus Med Rev; 1994 Jan; 8(1):59-75. PubMed ID: 8136608
    [No Abstract]   [Full Text] [Related]  

  • 6. [Minimal residual disease].
    Francia di Celle P; Foà R
    Haematologica; 1991 Jun; 76 Suppl 3():303-10. PubMed ID: 1752527
    [No Abstract]   [Full Text] [Related]  

  • 7. Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection.
    Cilloni D; Gottardi E; Fava M; Messa F; Carturan S; Busca A; Guerrasio A; Saglio G
    Blood; 2003 Jul; 102(2):773-4; author reply 774. PubMed ID: 12835231
    [No Abstract]   [Full Text] [Related]  

  • 8. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal in vitro differentiation of clonogenic B-cells in common acute lymphoblastic leukemia in complete remission. A marker for minimal residual disease?
    Bréard J; Mathé G; Consolini R
    Suppl J Med Oncol Tumor Pharmacother; 1988; 1():47-50. PubMed ID: 2977810
    [No Abstract]   [Full Text] [Related]  

  • 10. Flow cytometric identification of intracellular antigens: detection of minimal residual leukemia.
    Gore S; Kastan M; Civin C
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():39-41. PubMed ID: 1697192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous bone marrow transplantation in acute non lymphocytic leukemia.
    Gorin NC
    Rev Fr Transfus Immunohematol; 1985 Nov; 28(5):463-75. PubMed ID: 3912924
    [No Abstract]   [Full Text] [Related]  

  • 12. Cellular dynamics of leukemias.
    Raza A; Preisler HD
    Crit Rev Oncog; 1990; 1(4):373-88. PubMed ID: 2083288
    [No Abstract]   [Full Text] [Related]  

  • 13. Phenotypic heterogeneity in acute leukemia.
    Ryan DH
    Clin Chim Acta; 1992 Mar; 206(1-2):9-23. PubMed ID: 1572082
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection of central nervous system involvement in patients with leukemia or non-Hodgkin's lymphoma by immunological marker analysis of cerebrospinal fluid cells.
    Hooijkaas H; Adriaansen HJ; van Dongen JJ
    Cancer Treat Res; 1988; 38():149-71. PubMed ID: 2908594
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunologic approaches to the classification of lymphomas and lymphoid leukemias.
    Foon KA; Gale RP; Todd RF
    Cancer Treat Res; 1988; 38():1-30. PubMed ID: 2908593
    [No Abstract]   [Full Text] [Related]  

  • 16. Bone marrow trephine biopsies as a source of nucleic acids for molecular diagnosis of haematological neoplasms.
    Fey MF; Theilkäs L; Tobler A
    Br J Haematol; 1990 Feb; 74(2):229-31. PubMed ID: 2317459
    [No Abstract]   [Full Text] [Related]  

  • 17. Autologous transplantation of an immunomagnetic bead purged marrow in patients with relapsed acute lymphoblastic leukemia.
    Körbling M; Knauf W; Funderud S; Kvalheim G; Hunstein W
    Haematologica; 1991 Mar; 76 Suppl 1():29-36. PubMed ID: 1650742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
    Kainz B; Fonatsch C; Schwarzinger I; Sperr WR; Jäger U; Gaiger A
    Haematologica; 2005 May; 90(5):695-6. PubMed ID: 15921390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results.
    Vogler WR; Olson AC; Berdel WE; Okamoto S; Glasser L
    Prog Clin Biol Res; 1990; 333():1-18; discussion 19-20. PubMed ID: 2308973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the heterogeneity of minimal residual disease in acute leukemia.
    Hagenbeek A; Martens AC
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():9-12. PubMed ID: 2713565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.